UBS Global Biopharma Conference - CARDIFF ONCOLOGY INC
Financial Performance:
- No specific revenue, earnings, or profit margin figures provided as the company is a pre-commercial clinical-stage biopharmaceutical firm.
- Cash Position: Approximately $34 million in cash as of the end of the third quarter.
- Runway: Current cash reserves are sufficient to fund operations through the end of the third quarter of 2027.
- Cost Management: Emphasis on staged trial initiation to optimize capital efficiency while launching Phase 3.
Guidance and Future Outlook:
- Phase 3 Enrollment: Targeting staged initiation of the Phase 3 trial (CARD004) in the first quarter of 2027.
- Regulatory Path: Aiming for both Accelerated Approval (based on Overall Response Rate and durability) and Full Approval (based on Progression-Free Survival) within the same Phase 3 study.
- New Indication Development: Advancing monotherapy data for Chronic Myelomonocytic Leukemia (CMML), with updated results expected at the upcoming American Society of Hematology (ASH) meeting in December.
- Long-term Goal: To establish the drug as a standard-of-care first-line treatment for Pan-RAS metastatic colorectal cancer (mCRC), a market with no new innovations in 20+ years.
Business Segments and Product Lines:
- Core Asset: Onvancitib (PLK1 inhibitor), now with Fast-Track designation for RAS-mutated mCRC.
- Target Indication: First-line treatment for Pan-RAS (NRAS, KRAS, and others) metastatic colorectal cancer.
- Combination Strategy: Optimized regimen identified as Onvancitib 30mg + FOLFIRI + Bevacizumab; demonstrated superior efficacy vs. FOLFOX combinations.
- Secondary Indications:
- CMML: Investigating monotherapy in relapsed/refractory settings; showing ~40% response rate.
- Small Cell Lung Cancer: Recently received Orphan Drug designation.
- Regulatory Milestones: Completed End-of-Phase 2 meeting with the FDA; selected dose and regimen; received Orphan Drug Designation for CMML and SCLC.
Market and Competitive Landscape:
- Unmet Need: ~50% of mCRC patients harbor RAS mutations with poor prognosis; no new therapies approved in this space for over two decades.
- Competitive Gap: Competitors are focusing on MSS (microsatellite stable) populations or specific G12C inhibitors, which represent only a small fraction of RAS-mutated patients; Cardiff targets the broader Pan-RAS population.
- Standard of Care Comparison: Current standard (chemo + Bevacizumab) lacks significant impact on Overall Response Rate (ORR); Cardiff's data shows ~30% improvement in ORR (70% vs. 42%).
- Market Share Goal: Potential to change clinical practice and become the new standard for RAS-mutated mCRC if Phase 3 results confirm PFS benefits.
Risks and Challenges:
- Trial Dependency: Success is contingent on the ongoing Phase 3 trial meeting its PFS endpoints; Phase 2 was not powered for PFS.
- Funding: While current cash covers until Q3 2027, the company must successfully raise additional capital or secure partnerships to sustain the Phase 3 timeline through commercialization.
- Regulatory Uncertainty: While Fast-Track and Orphan Designations are secured, final FDA acceptance of PFS as a primary endpoint for Full Approval and ORR for Accelerated Approval remains subject to data maturity.
- Tolerability: While early data suggests a manageable safety profile in first-line combinations, long-term tolerability remains a critical variable for patient retention.
Management Commentary and Tone:
- Tone: Highly confident and optimistic; management emphasizes "compelling efficacy," "synergy," and the potential to "change practice."
- Strategic Focus: Strong emphasis on the mechanistic rationale (PLK1 inhibition + DNA repair blockade via Irinotecan) explaining the efficacy differences between FOLFIRI and FOLFOX backbones.
- Team Execution: Highlighted successful regulatory interactions, clear dose selection, and preparation for rapid Phase 3 initiation.
- Clinical Relevance: Management stressed that patients with "hard-to-treat" features (liver metastases, multi-organ involvement) showed clear benefits, validating the drug's utility in the worst-case scenarios.
Analyst Questions and Answers:
- Note: The provided transcript is a presentation by the CEO and does not contain a Q&A session with analysts.
- Key Clarifications (Management Self-Addressed):
- Dose Selection: Confirmed 30mg Onvancitib is the optimal dose for Phase 3 based on dose-dependent improvements in response depth.
- Chemo Regimen: Explained the biological synergy between Onvancitib and Irinotecan (HIF-1-alpha inhibition and DNA repair blockade) versus the lack of synergy with Oxaliplatin (FOLFOX), justifying the choice of FOLFIRI.
- Surgical Outcomes: Noted a trend of patients in the 30mg arm achieving tumor shrinkage sufficient for curative surgery, a metric not captured in the PFS analysis of the small Phase 2 cohort.
Other Key Points:
- Mechanism of Action: Onvancitib blocks PLK1 (essential for cell division in RAS-mutated cells) and inhibits HIF-1-alpha (angiogenesis), creating a dual-block on tumor growth and blood supply.
- Patient Demographics: The Phase 2 study included patients with liver metastases and multi-organ involvement, who typically have the poorest prognosis, yet still showed drug benefit.
- Durability: Patients on the 30mg + FOLFIRI + Bevacizumab arm remained on treatment for >21 months in some cases, compared to median PFS of ~11 months for the control arm.
- Global Reach: Regulatory interactions have occurred with both US FDA and European regulators, with European feedback expected shortly.
- Company
- CARDIFF ONCOLOGY INC
- Keywords
- CARDIFF ONCOLOGY INC